|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||84.62 - 85.45|
|52 Week Range||78.78 - 95.00|
|Beta (5Y Monthly)||0.56|
|PE Ratio (TTM)||19.74|
|Forward Dividend & Yield||3.22 (3.84%)|
|Ex-Dividend Date||Mar. 04, 2021|
|1y Target Est||N/A|
For example, at their current share prices, both Novartis (NYSE: NVS) and Chevron (NYSE: CVX) yield more than 3%. If you buy shares of Novartis today, you'll collect around 3.7% just in dividend income at the current payout level. The pharmaceutical company has increased its annual dividend payments for 24 years in a row -- and a hike this year would make it a Dividend Aristocrat.
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. “I am delighted to welcome Cintia to our leadership team. She brings extensive commercial experience, including in cell and gene therapy, that will be key as we prepare to submit our first BLA for afami-cel this year, and buil
The FDA bestows an Orphan Drug status to Ionis' (IONS) investigational medicine, eplontersen, for treating people living with transthyretin-mediated amyloidosis.